UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with IC50 of 2.9 nM and Ki of 4.3 nM. UNC569 also inhibited Axl and Tyro3 with IC50 of 37 nM and 48 nM, respectively.
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with IC50 of 2.9 nM and Ki of 4.3 nM. UNC569 also inhibited Axl and Tyro3 with IC50 of 37 nM and 48 nM, respectively.
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with IC50 of 2.9 nM and Ki of 4.3 nM. UNC569 also inhibited Axl and Tyro3 with IC50 of 37 nM and 48 nM, respectively.
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with IC50 of 2.9 nM and Ki of 4.3 nM. UNC569 also inhibited Axl and Tyro3 with IC50 of 37 nM and 48 nM, respectively.
UNC669 is a potent and selective MBT (malignant brain tumor) inhibitor with IC50 of 6 μM for L3MBTL1, 5- and 11-fold selective over L3MBTL3 and L3MBTL4.
UNC669 is a potent and selective MBT (malignant brain tumor) inhibitor with IC50 of 6 μM for L3MBTL1, 5- and 11-fold selective over L3MBTL3 and L3MBTL4.
UNC669 is a potent and selective MBT (malignant brain tumor) inhibitor with IC50 of 6 μM for L3MBTL1, 5- and 11-fold selective over L3MBTL3 and L3MBTL4.
UNC669 is a potent and selective MBT (malignant brain tumor) inhibitor with IC50 of 6 μM for L3MBTL1, 5- and 11-fold selective over L3MBTL3 and L3MBTL4.
Unecritinib is a potent EGFR tyrosine kinase inhibitor that inhibits ALK, ROS1, and MET and has anticancer activity. Unecritinib is indicated for use in studies of solid tumors and ALK-positive anaplastic large cell lymphoma.